DNA and TLR-4-based adjuvant protein vaccine (Inovio Pharmaceuticals/NCI/National Institute of Allergy and Infectious Diseases/Infectious Disease Research Institute/Duke University Medical Center)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameDNA and TLR-4-based adjuvant protein vaccine (Inovio Pharmaceuticals/NCI/National Institute of Allergy and Infectious Diseases/Infectious Disease Research Institute/Duke University Medical Center)
Drug Alias NameDNA and GLA-IMQ adjuvanted protein vaccine (Inovio Pharmaceuticals/NCI/National Institute of Allergy and Infectious Diseases/Infectious Disease Research Institute/Duke University Medical Center)DNA and GLA-LSQ adjuvanted protein vaccine (Inovio Pharmaceuticals/NCI/National Institute of Allergy and Infectious Diseases/Infectious Disease Research Institute/Duke University Medical Center)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInovio Pharmaceuticals IncAccess to Advanced Health InstituteDuke University Medical Center +[5] 
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A